Triapine for Endometrial Carcinoma

Virginia Commonwealth University/Massey Cancer Center, Richmond, VA
Endometrial CarcinomaTriapine - Drug
What conditions do you have?

Study Summary

This trial is testing the anti-cancer drug triapine in women with uterine cancer. It will use markers from tissue samples to see if the drug stops the growth of tumor cells.

Eligible Conditions
  • Endometrial Serous Carcinoma

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase < 1

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Up to 6-8 hours post-triapine infusion

Whole exome sequencing (WES) analysis
Hour 24
Pharmacokinetic (PK) analysis
Baseline, post-triapine infusion, surgical resection
Single-cell transcriptome analysis
Hour 8
Pharmacodynamic response
Up to day 42
Incidence of adverse events

Trial Safety

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

Treatment (triapine, surgical resection)
1 of 1

Experimental Treatment

12 Total Participants · 1 Treatment Group

Primary Treatment: Triapine · No Placebo Group · Phase < 1

Treatment (triapine, surgical resection)Experimental Group · 4 Interventions: Biopsy, Resection, Biospecimen Collection, Triapine · Intervention Types: Procedure, Procedure, Procedure, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4
Completed Phase 2
Biospecimen Collection
Completed Phase 1
Not yet FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 6-8 hours post-triapine infusion

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,272 Previous Clinical Trials
41,230,716 Total Patients Enrolled
15 Trials studying Endometrial Carcinoma
9,251 Patients Enrolled for Endometrial Carcinoma
Rebecca L StonePrincipal InvestigatorJHU Sidney Kimmel Comprehensive Cancer Center LAO

Eligibility Criteria

Age 18+ · Female Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You can participate in this trial if you had cancer before, or have it now, but it won't interfere with the safety or effectiveness of the investigational treatment.

Frequently Asked Questions

What is the current participation levels of this investigation?

"Affirmative. Information on suggests that this research study, initially published on November 11th 2020, is still recruiting volunteers. 12 individuals are needed from 6 different medical facilities to complete the trial." - Anonymous Online Contributor

Unverified Answer

What is the geographic distribution of sites participating in this trial?

"Six medical centres in total are participating in the trial, including University of Miami Miller School of Medicine-Sylvester Cancer Center, UM Sylvester Comprehensive Cancer Center at Deerfield Beach and UM Sylvester Comprehensive Cancer Center at Plantation. Additionally, other three sites can be found throughout the country." - Anonymous Online Contributor

Unverified Answer

Is there still room for participation in this research endeavor?

"Indeed, the database conveys that this experiment is presently recruiting participants. It was initially publicized on November 11th 2020 and its entry was last revised on November 30th 2022. A total of 12 individuals from 6 distinct sites need to be recruited for it." - Anonymous Online Contributor

Unverified Answer

Are there any precedent trials utilizing Triapine that have been conducted?

"Research into triapine began in 2016 at Medical Oncology and Hematology Associates-Laurel, leading to 65 completed trials. Currently, 4 active studies are being conducted across Miami, Florida." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.